Effect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive Patients

American Journal of Hypertension

Volumn 20, Issue 4, 2007, Pages 443-450

  Pasini, Anna Fratta ^a   Garbin, Ulisse ^a   Nava, Maria Cristina ^a   Stranieri, Chiara ^a   Pellegrini, Michele ^b   Boccioletti, Veronica ^a   Luchetta, Maria Laura ^b   Fabrizzi, Paolo ^b   Lo Cascio, Vincenzo ^a   Cominacini, Luciano ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Laboratori Guidotti SpA   (Italy)

Author keywords

ACE inhibitor; adhesion molecules; Endothelial dysfunction; hypertension; oxidative stress; sulfhydryl group

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; METHYLTESTOSTERONE; OXIDIZED LOW DENSITY LIPOPROTEIN; RAMIPRIL; THIOL GROUP; VASCULAR CELL ADHESION MOLECULE 1; ZOFENOPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOTHELIUM; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MALE; METABOLIC PARAMETERS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATENOLOL; BLOOD GLUCOSE; BLOOD PRESSURE; CAPTOPRIL; CELL ADHESION MOLECULES; CHOLESTEROL, HDL; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; RAMIPRIL; SULFHYDRYL COMPOUNDS; TRIGLYCERIDES; VASODILATION;

EID: 33947321294     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.09.020     Document Type: Article

References (30)

1. Panza J.A., Quyyumi A.A., Brush Jr. J.E., and Epstein S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323 (1990) 22-27
2. Lassègue B., and Griendling K.K. Reactive oxygen species in hypertension. An update. Am J Hypertens 17 (2004) 852-860
3. Irani K. Oxidant signalling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 87 (2000) 179-183
4. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., and Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9 (1995) 899-909
5. Yu B.P. Cellular defenses against damage from reactive oxygen species. Physiol Rev 74 (1994) 139-162
6. Kedziora-Kornatowska K., Czuczejko J., Pawluk H., Kornatowski T., Motyl J., Szadujkis-Szadurski L., Szewczyk-Golec K., and Kedziora J. The markers of oxidative stress and activity of the antioxidant system in the blood of elderly patients with essential arterial hypertension. Cell Mol Biol Lett 9 (2004) 635-641
7. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., Diez J., Drexler H., Ferrari R., Van Gilst W., Hansson L., Hornig B., Husain A., Johnston C., Lazar H., Lonn E., Luscher T., Mancini J., Mimran A., Pepine C., Rabelink T., Remme W., Ruilope L., Ruzicka M., Schunkert H., Swedberg K., Unger T., Vaughan D., and Weber M. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 16 (2002) 149-160
8. Mira M.L., Silva M.M., and Manso C.F. The scavenging of oxygen free radicals by angiotensin converting enzyme inhibitors: the importance of the sulfhydryl group in the chemical structure of the compounds. Ann N Y Acad Sci 723 (1994) 439-441
9. Evangelista S., and Manzini S. Antioxidant and cardioprotective properties of the sulfhydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 33 (2005) 42-54
10. Scribner A.W., Loscalzo J., and Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 482 (2003) 95-99
11. Cominacini L., Fratta Pasini A., Garbin U., Evangelista S., Crea A., Tagliacozzi D., Nava C., Davoli A., and Lo Cascio V. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 15 (2002) 891-895
12. Bertrand M.E. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 10 (2004) 1559-1569
13. Fratta Pasini A., Garbin U., Nava M.C., Stranieri C., Davoli A., Sawamura T., Lo Cascio V., and Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23 (2005) 589-596
14. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., Vallance P., Vita J., Vogel R., and International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
15. Napoli C., Sica V., de Nigris F., Pignalosa O., Condorelli M., Ignarro L.J., and Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 148 (2004) e5
16. Chopra M., Beswick H., Clapperton M., Dargie H.J., Smith W.E., and McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 19 (1992) 330-340
17. Grover G.J., Sleph P.G., Dzwonczyk S., Wang P., Fung W., Tobias D., and Cushman D.W. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection. J Pharmacol Exp Ther 257 (1991) 919-929
18. Ferri C., Desideri G., Baldoncini R., Bellini C., De Angelis C., Mazzocchi C., and Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 47 (1998) 660-667
19. Noble M., Smith J., Power J., and Mayer-Proschel M. Redox state as a central modulator of precursor cell function. Ann N Y Acad Sci 991 (2003) 251-271
20. Dal Monte M., Del Corso A., Moschini R., Cappiello M., Amodeo P., and Mura U. Zofenoprilat-glutathione mixed disulfide as a specific S-thiolating agent of bovine lens aldose reductase. Antioxid Redox Signal 7 (2005) 841-848
21. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
22. Ghiadoni L., Magagna A., Versari D., Kardasz I., Huang Y., Taddei S., and Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41 (2003) 1281-1286
23. Buikema H., Monnink S.H., Tio R.A., Crijns H.J., de Zeeuw D., and van Gilst W.H. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 130 (2000) 1999-2007
24. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 20 (2000) 2032-2037
25. Horowitz J.D., Antman E.M., Lorell B.H., Barry W.H., and Smith T.W. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 68 (1983) 1247-1253
26. MacMahon S., Sharpe N., Gamble G., Clague A., Mhurchu C.N., Clark T., Hart H., Scott J., and White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 36 (2000) 438-443
27. Lonn E., Yusuf S., Dzavik V., Doris C., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W., Teo K., and SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103 (2001) 919-925
28. Hornig B., Landmesser U., Kohler C., Ahlersmann D., Spiekermann S., Christoph A., Tatge H., and Drexler H. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103 (2001) 799-805
29. Koh K.K., Quon M.J., Han S.H., Ahn J.Y., Jin D.K., Kim H.S., Kim D.S., and Shin E.K. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005) 1088-1093
30. Koh K.K., Son J.W., Ahn J.Y., Kim D.S., Jin D.K., Kim H.S., Han S.H., Seo Y.H., Chung W.J., Kang W.C., and Shin E.K. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 44 (2004) 180-185